
DELFI Diagnostics│Saving Lives Through Early Cancer Detection
These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early …
Leadership Team - DELFI
These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early …
Fragmentomics Platform - DELFI
Unlocking a Vast Trove of Diagnostic Data Our unique fragmentomics technology isn’t limited to the small number of mutations or alterations detected by other liquid biopsy methods. We see a bigger …
Mission - DELFI
Widely Available Screening Effective cancer screening requires a test accessible to everyone who needs one. DELFI’s machine learning tools work with commonly used lab methods and instruments, …
Health Systems - DELFI
It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory …
Contact - DELFI
Contact us Have questions or need more information? We’d love to hear from you. Considering joining our team? Learn more Call 800-589-2182 Email info@delfidiagnostics.com Send 1810 Embarcadero …
Newsroom - DELFI
Dec 1, 2025 · Hackensack Meridian Health Partners with DELFI Diagnostics, supported by a grant from Lilly to Improve Lung Cancer Screening Adherence with Innovative Blood Test
Careers - DELFI
DELFI is expanding its team of top talent to help people live longer, healthier, cancer-free lives through widely available, high-performing cancer screening tests.
- [PDF]
DELFI Diagnostics
It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory …
DELFI-TF Treatment Monitoring - DELFI
While cell-free DNA offers tremendous potential for cancer diagnostics, traditional approaches are constrained by the need for tumor-specific mutation data. DELFI overcomes this fundamental …